- Sourcews Report
- File
- HTML
- Size
- 23 Ko
- URL response
- 100%
- Source quality
- 92%
- Sourcews Explorer
Crucell Announces STARŪ Research License Agreement with Toyobo Gene Analysis Co. LTD
29.04.08 - 09:02 ... source : Crucell
... . Leiden, The Netherlands, 29 April 2008 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STARŪ research license agreement with Toyobo Gene Analysis Co. LTD. Under the agreement, Toyobo Gene Analysis will evaluate Crucell's STARŪ technology for generating cell lines for the production of recombinant proteins for third-party customers. Financial details of the agreement were not disclosed. About STARŪ Technology STARŪ technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6Ū human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STARŪ technology contains genetic elements, ...» Next (HTML)
Similar news
100% | 08.04.08 - 17:44 ... source : Crucell
... company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STARŪ research license agreement with Celltrion, Inc. for the production of recombinant proteins. Under the agreement, Celltrion will evaluate Crucell's STARŪ technology for generating cell lines for ...
99% | 25.03.08 - 17:21 ... source : Crucell
... Crucell N.V. today announced a non-exclusive STARŪ research license agreement with biopharmaceutical company Medarex for the production of monoclonal antibodies. Financial details of the agreement were not disclosed. About STARŪ Technology STARŪ technology is a production technology that is particularly ...
98% | 03.03.08 - 09:46 ... source : Crucell
... Crucell N.V. today announced that it has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain ...
91% | 03.04.08 - 15:06 ... source : Crucell
... in new HIV vaccine Leiden, The Netherlands, 3 April 2008 - Dutch biotechnology company Crucell N.V. today announced that the novel recombinant adenovirus serotype 26 (rAd26) vector, which is jointly developed by Crucell and the Beth Israel Deaconess Medical Center ...
89% | 17.03.08 - 09:17 ... source : Crucell
... Crucell N.V. and DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced that German-based MorphoSys AG has decided to extend the PER.C6Ū technology licensing agreement entered in September 2004, exercising an option for clinical and commercial production of ...
